AdipoGen Life Sciences COVID-19 antiviral research compounds

Wednesday, 27 May, 2020 | Supplied by: Sapphire Bioscience

There are no approved drugs to treat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19). Existing drugs, which have a known favourable safety profile, are being examined for strategies to treat the disease and fast-track a treatment plan. Several influenza and HIV drugs are currently undergoing clinical trial in coronavirus patients. The rational selection of drugs already on the market is being made based on their ability to inhibit any proteins essential for virus-receptor interaction and/or viral life cycle.

AdipoGen Life Sciences’ range of Small Molecule SARS-CoV-2 Inhibitors and Modulators offers potential tools for in vitro studies of COVID-19. The company’s product range includes research compounds targeting viral transcription, replication and maturation.

Phone: 02 9698 2022
Related Products

CellSera foetal bovine serum

CellSera's foetal bovine serum is sterile filtered using Sartorius Stedim Biotech triple 0.1...

Novozymes Remify Everis 100 L enzyme solution for surgical device cleaning

The product is a phosphodiesterase (PDE) — a nuclease — that speeds up reactions and...

AdipoGen Life Sciences immunometabolism research compounds

AdipoGen Life Sciences offers a broad range of immunometabolism small molecule modulators of...

  • All content Copyright © 2020 Westwick-Farrow Pty Ltd